All In Biotech

Drug Trial Radar · NCT06708455

Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

65

Planned (sponsor's estimate)

Start

Mar 1, 2027

Primary completion

Mar 1, 2029

Study completion Sep 30, 2029

Sponsor

Lead sponsor
Rapa Therapeutics LLCIndustry
Sponsor type
Industry
First posted
Nov 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The protocol is a Simon's 2-stage, non-randomized, open label, multi-site, phase 2 trial for patients with advanced metastatic, recurrent and unresectable malignant melanoma that has recurred or relapsed after prior anti-PD-(L)1 therapy.

Conditions

  • Malignant Melanoma With Metastasis
  • Malignant Melanoma
  • Malignant Melanoma Stage IIIc
  • Malignant Melanoma Stage IV

Interventions

  • RAPA-201 Rapamycin Resistant T CellsBiological

    Autologous Rapamycin-Resistant Th1/Tc1 Cells

  • Chemotherapy Prior to RAPA-201 TherapyDrug

    Carboplatin + Paclitaxel Regimen (CP Regimen)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of RAPA-201 Cell TherapyTime frame: 18 months (6 mo. of treatment; 12 mo of clinical follow-up)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hackensack University Medical Center

    Hackensack, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.